{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Pembrolizumab With Etoposide/Platinum for First-line Small Cell lung Cancer

Activity Steps

Description

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify results from the KEYNOTE-604 study evaluating the addition of pembrolizumab to etoposide and platinum (EP) for the treatment of SCLC.
  2. Assess the benefit of adding an immune checkpoint inhibitor to standard therapy for the treatment of SCLC.
Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: OT1122
Published: November 2022
Expires: 10/31/2024
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: DiBash Kumar DAS, PHD
Categories: Hematology , Oncology
Specialties: Hematology, Oncology